Log In / Register
CycloLab’s polymer for atherosclerosis
15 January, 2020
Kim et al. reported in Journal of Controlled Release on recent results obtained by using beta-cyclodextrin polymer of CycloLab.
Due to the large size of the polymer molecules compared to HPBCD they are not eliminated through the kidney, accumulated in the atherosclerotic plaques and remove both intra- and extracellular cholesterol from plaques while exhibiting reduced cholesterol removal from cell membrane resulting in reduced ototoxicity, typical side effect for non-polymer CDs.
BACK TO NEWS